Toggle Main Menu Toggle Search

Open Access padlockePrints

A cluster randomised, crossover, registry-embedded clinical trial of proton pump inhibitors versus histamine-2 receptor blockers for ulcer prophylaxis therapy in the intensive care unit (PEPTIC study): study protocol

Lookup NU author(s): Dr Stephen Wright

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

BACKGROUND: The balance of risks and benefits with using proton pump inhibitors (PPIs) versus histamine-2 receptor blockers (H2RB) for stress ulcer prophylaxis in patients who are invasively ventilated in the intensive care unit (ICU) is uncertain. OBJECTIVE: To describe the study protocol and statistical analysis plan for the Proton Pump Inhibitors versus Histamine-2 Receptor Blockers for Ulcer Prophylaxis Therapy in the Intensive Care Unit (PEPTIC) study. DESIGN, SETTING AND PARTICIPANTS: Protocol for a prospective, multicentre, randomised, open-label, cluster crossover, registry-embedded trial to be conducted in 50 ICUs in Australia, Canada, Ireland, New Zealand and the United Kingdom. The PEPTIC study will compare two approaches to stress ulcer prophylaxis in mechanically ventilated adults implemented at the level of the ICU. One approach is to use PPIs as the default therapy and the other approach is to use H2RBs as the default therapy when stress ulcer prophylaxis is prescribed. Each ICU, by random allocation, will use one approach for 6 months and will then switch to the opposite approach for the next 6 months. The PEPTIC study began recruitment in August 2016 and will complete recruitment in January 2019. MAIN OUTCOME MEASURES: The primary end point will be in-hospital mortality. Secondary outcomes include clinically significant upper gastrointestinal bleeding, Clostridium difficile infection, ICU length of stay and hospital length of stay. RESULTS AND CONCLUSIONS: The PEPTIC study will compare the effect on in-hospital mortality of implementing, at the level of the ICU, the use of PPI as the preferred agent for stress ulcer prophylaxis in mechanically ventilated adults in the ICU with using H2RB as the preferred agent. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTRN 12616000481471).


Publication metadata

Author(s): Young PJ, Bagshaw SM, Forbes A, Nichol A, Wright SE, Bellomo R, Bailey MJ, Beasley RW, Eastwood GM, Festa M, Gattas D, van Haren F, Litton E, Mouncey PR, Navarra L, Pilcher D, Mackle DM, McArthur CJ, McGuinness SP, Saxena MK, Webb S, Rowan KM

Publication type: Article

Publication status: Published

Journal: Critical Care and Resuscitation

Year: 2018

Volume: 20

Issue: 3

Pages: 182-189

Print publication date: 01/09/2018

Acceptance date: 02/04/2018

ISSN (print): 1441-2772

Publisher: Australasian Academy of Critical Care Medicine

URL: https://cicm.org.au/Resources/Publications/Journal/2010-2020

PubMed id: 30153780


Share